Zusammenfassung
Weichteilsarkome (WTS) stellen eine sehr heterogene Gruppe maligner Tumoren dar. Sie entstehen primär in den Weichteilen, sind mesenchymaler Herkunft und bilden die viertgrößte Gruppe solider Tumoren im Kindesalter. Der häufigste bei Kindern auftretende Tumor aus der Gruppe der Weichteilsarkome ist das Rhabdomyosarkom (RMS).
Wie andere Krebserkrankungen bei Kindern und Jugendlichen werden Weichteilsarkome in der Regel in multizentrischen Therapieoptimierungsstudien der Deutschen Gesellschaft für Pädiatrische Hämatologie und Onkologie (GPOH) behandelt. Solche Therapiestudien machen präzise Vorschriften für Diagnostik und Therapie. Darüber hinaus widmet sich dieser Beitrag der Tumorbiologie und Pathophysiologie, der Nachsorge und der Prognose dieses pädiatrischen Malignoms.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Admiraal R et al (2010) High-dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma (Review). The Cochrane Collaboration. Cochrane Database Syst Rev. 2010 Dec 8; (12): CD006669
Carli M et al. (2003) Ifosfamide in pediatric solid tumors. Oncology 65 (Suppl 2): 99–104
Casanova M et al. (2002) Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 94 (12): 3263–328
Chui CH et al. (2002) Is reexcision in pediatric nonrhabdomyosarcoma soft tissue sarcoma necessary after an initial unplanned resection? J Pediatr Surg 37 (10): 1424–1429
Cosetti M et al. (2002) Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 24 (2): 101–105
Crist W et al. (1995) The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13 (3): 610–630
Crist WM et al. (2001) Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 19 (12): 3091–3102
Dantonello T et al (2008) Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol 26: 406–413
Dantonello T et al. (2009) The cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol 27:1446–1455
Flamant F et al. (1998) Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 34 (7): 1050–1062
Gupta AA. Pappo AS (2006) New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children. Future Oncol 2 (5): 675–685
Hennekam (2003) Principles and practice of pediatric oncology. In: Pizzo PA, Poplack DG (eds) Wolters Kluwer, Lippincott Wiliams & Wilkins Philadelphia, Baltimore, New York, p 201
Heyn R et al. (1993) Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J Clin Oncol 11 (2): 262–270
Klingebiel T et al. (1998) Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. Med Pediatr Oncol 30 (5): 269–275
Klingebiel T et al. (2008) Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the CWS JD 95 trial. Ped Blood Cancer 50: 739–745
Koscielniak E et al. (1994) [Improved local tumor control by early and risk-adjusted use of radiotherapy in primary non-resectable rhabdomyosarcomas: results of CWS 81 and 86 studies]. Klin Padiatr 206 (4): 269–276
Koscielniak E et al. (1999) Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 17 (12): 3706–3719
Kratz CP et al. (2007) Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome. Hum Mol Genet 16 (4): 374–379
Krischer JP et al. (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 15 (4): 1544–1552
Marina NM et al. (2000) Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. J Pediatr Hematol Oncol 22 (2): 112–118
Martelli H et al. (1999) Conservative treatment for girls with nonmetastatic rhabdomyosarcoma of the genital tract: A report from the Study Committee of the International Society of Pediatric Oncology. J Clin Oncol 17: 2117–21122
Mattke AC et al (2009) Does the time-point of relapse influence outcome in pediatric rhabdomyosarcomas? Ped Blood Cancer 52:772–776
Newton WA Jr et al. (1995) Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification – an Intergroup Rhabdomyosarcoma Study. Cancer 76 (6): 1073–85
Oberlin O et al. (1992) No benefit of ifosfamide in Ewing’s sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 10 (9): 1407–1412
Pappo AS et al. (1999) Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 17 (11): 3487–93
Ruymann FB (2003) The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore? Curr Oncol Rep 5 (6): 505–509
Schwartzbaum JA et al. (1991) An exploratory study of environmental and medical factors potentially related to childhood cancer. Med Pediatr Oncol 19 (2): 115–121
Seitz G et al (2011) Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: a report from the Cooperative Soft Tissue Sarcoma trial CWS-96. Ped Blood Cancer 56 (5): 718–724
Siebenrock KA, Hertel R, Ganz R (2000) Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery. Arch Orthop Trauma Surg 120 (1–2): 65–69
Stegmaier S et al. (2011) Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS). Pediatr Blood Cancer 57(3): 406–414
Stevens MC et al. (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology – SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23 (12): 2618–2628
Wachtel M et al. (2006) Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 24 (5): 816–822
Williamson D et al. (2010) Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 28(13): 2151–2158
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Klingebiel, T., Koscielniak, E. (2014). Weichteilsarkome. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35032-0_32
Download citation
DOI: https://doi.org/10.1007/978-3-642-35032-0_32
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35031-3
Online ISBN: 978-3-642-35032-0
eBook Packages: Medicine (German Language)